MELBOURNE: Adherium Limited (ASX: ADR) has appointed Rick Legleiter as Chief Executive Officer of Adherium, a news release said.
The Board also announced the appointment of George Baran as a Non-Executive Director. Mike Motion, Adherium’s current CEO and Executive Director, has made the decision to step down from the Board and CEO position for personal reasons and will continue to support the business in a consulting capacity. Rick’s and George’s appointments take place with immediate effect.
The Adherium Board believes, given the conditionality of the Respiri Takeover Offer, that in the best interests of Adherium shareholders, it must continue “business as usual”.
The appointment of Rick Legleiter has been made after an extensive executive search. It is intended that Rick be based in Melbourne, Australia conditional on obtaining an appropriate visa and travel exemption entitling him to enter from the US and lawfully work in Australia.
James Ward-Lilley, Chairman of Adherium commented “Rick brings to the business a strong career track record of global systems business development and partnering at Siemens along with successful Australia-based CEO business turnaround performance whilst at Universal Biosensors.
Rick combines a clear vision for the business with strong detail focus and execution orientation. The intention is for Rick to be based in Melbourne, where he will directly oversee the further recruitment and development of the Adherium team in Australia.
I would like to thank Mike for his contribution and leadership of the business through the challenging COVID period, during which time Adherium has made important progress clarifying its strategy, moving forward the development of physiologically enabled inhalation sensors and the progression of commercial pilot programmes with HGE Health and Monaghan Medical (Trudell) in the United States. I am also delighted to welcome George Baran to the Board, replacing Bryan Mogridge who stepped down from the Board in January.
George brings over 35 years of medical device industry experience to the Board including business and technical leadership in the acquisition and development of novel medical device technologies. George serves as Executive Chair of the Trudell Medical Limited Board of Directors and his appointment reflects
Trudell’s commitment to Adherium’s success both as investors and as strategic partners developing integrated digital solutions for a range of devices in the respiratory setting”.
Adherium Limited (ASX: ADR) is a provider of digital health solutions and a global leader in connected respiratory medical devices, with more than 170,000 sold globally. The Company develops, manufactures and supplies a broad range of connected medical devices for respiratory medications for patients, pharmaceutical companies, healthcare providers and contract research organisations.
Adherium Ltd ASX: ADR
Share price
0.016 AUD −0.0010 (5.88%)
13 May, 12:05 pm GMT+10 · Disclaimer